Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | KIT | P10721 | 3/20 | 0.43 |
| ▸ | GRM5 | P41594 | 6/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 6/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30583903 | 0.92 | TLR7 (0.47) | TLR7NAMPTGPR119KITGRM5 | |
| SCHEMBL30453607 | 0.89 | CNR1 (0.46) | TLR7GPR119KITGRM5GRM1 | |
| SCHEMBL22391649 | 0.89 | CNR1 (0.46) | TLR7GPR119KITGRM5GRM1 | |
| SCHEMBL26914159 | 0.89 | GPR119 (0.46) | TLR7NAMPTGPR119KITGRM5 | |
| SCHEMBL24320715 | 0.88 | KDM1A (0.45) | TLR7NAMPTGPR119GRM5GRM1 | |
| SCHEMBL30284525 | 0.88 | GRM5 (0.44) | TLR7NAMPTGPR119KITGRM5 | |
| SCHEMBL22391814 | 0.88 | GRM5 (0.44) | TLR7NAMPTGPR119KITGRM5 | |
| SCHEMBL30583938 | 0.86 | QDPR (0.45) | TLR7NAMPTGPR119GRM5GRM1 | |
| SCHEMBL31306920 | 0.84 | GRM1 (0.47) | TLR7GPR119KITGRM5GRM1 | |
| SCHEMBL30583877 | 0.82 | GRM5 (0.47) | TLR7GPR119KITGRM5GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391760-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-12-07 | — | — | US | disclosed |
| WO-2022078407-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391760-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | TLR7 1125/4885NAMPT 2068/4885GPR119 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.